JLE

European Journal of Dermatology

MENU

Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment? Volume 29, numéro 1, January-February 2019

Tableaux

Auteurs
1 University Hospital,
Pulmonology Department,
54000 Nancy, France
2 University of Lorraine,
EA 3450 DevAH,
Development, Adaptation, Cardio-Respiratory Regulations and Motor Control,
54000 Nancy, France
3 University Hospital,
Dermatology-Allergology Department,
54000 Nancy, France
4 Pasteur Institute,
Center for Innovation and Technological Research,
75000 Paris, France
5 Assistance Publique-Hôpitaux de Paris (AP-HP),
Armand-Trousseau Children Hospital,
Biochemistry Laboratory,
Allergy and Environment Team,
75000 Paris, France
6 University of Lorraine,
54000 Nancy, France

Omalizumab is a recombinant humanized monoclonal antibody (mAb) targeting IgE, produced using Chinese hamster ovary (CHO) cell culture. It has been approved for the treatment of severe allergic asthma (SAA) and chronic urticaria but not for allergic rhinitis (AR), atopic dermatitis (AD) or food allergy, despite some benefits against these diseases [1]. Omalizumab treatment associated with allergen immunotherapy (AIT) can increase the tolerability of AIT [1]. Some anaphylactic reactions have been [...]